|
|
| | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- Basic information |
| Product Name: | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- | | Synonyms: | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl-;DDO-7263;DDO-7263, 10 mM in DMSO;5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole | | CAS: | 2254004-96-9 | | MF: | C14H9F2N3O | | MW: | 273.24 | | EINECS: | | | Product Categories: | | | Mol File: | 2254004-96-9.mol | ![Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- Structure](CAS/20210305/GIF/2254004-96-9.gif) |
| | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- Chemical Properties |
| Boiling point | 403.2±55.0 °C(Predicted) | | density | 1.318±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 17.86 mg/mL (65.36 mM; ultrasonic and warming and heat to 60°C) | | form | Solid | | pka | 2.09±0.12(Predicted) | | color | White to off-white |
| | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- Usage And Synthesis |
| Uses | DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD)[1][2]. | | Biological Activity | DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD)[1][2].
DDO-7263 (20 μM; 2-24 h) can upregulate the protein levels of HO-1 and NQO1 in concentration-dependent manners[1]. DDO-7263 (2.5, 5, 10, 20, 40, 80 μM; 24 h) can upregulate the survival rate of PC12 and THP-Ms cell after 400 μM H2O2 in a concentration-dependent manner. DDO-7263 alone has no significant decrease on cell survival rate[1].
DDO-7263 (10-100 mg/kg/day; IP; for 10 days) improves the behavioral abnormalities induced by MPTP in mice, significantly attenuates chemically induced dopaminergic neuron loss of tyrosine hydroxylase (TH) in the substantia nigra (SN) and striatum of the mouse brain and inhibits the secretion of inflammatory factors[1]. DDO-7263 (7, 35, 70 mg/kg; IP) has a T1/2 of 3.32 hours and a Cmax of 1.38 mg/mL for rats[1]. | | in vivo | DDO-7263 (10-100 mg/kg/day; IP; for 10 days) improves the behavioral abnormalities induced by MPTP in mice, significantly attenuates chemically induced dopaminergic neuron loss of tyrosine hydroxylase (TH) in the substantia nigra (SN) and striatum of the mouse brain and inhibits the secretion of inflammatory factors[1].
DDO-7263 (7, 35, 70 mg/kg; IP) has a T1/2 of 3.32 hours and a Cmax of 1.38 mg/mL for rats[1].
| Animal Model: | Male C57BL/6 mice at 10 weeks of age and body weights of 22-26 g[1] | | Dosage: | 10, 50, 100 mg/kg | | Administration: | IP; daily for 10 days | | Result: | Improved the reduction of vertical spontaneous activity and mitigated the loss of balance coordination caused by MPTP (20 mg/kg/day; 7 days).
Protected dopaminergic neurons from MPTP.
Significantly downregulated the levels of pro-inflammatory factors, including IL-1β and TNF-α, in mouse plasma.
|
| Animal Model: | SD rats[1] | | Dosage: | 7, 35, 70 mg/kg (Pharmacokinetic Analysis) | | Administration: | IP | | Result: | Had a T1/2 of 3.32 hours and a Cmax of 1.38 mg/mL.
|
| | References | [1]. Li-Li Xu, et al. 5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic Biol Med. 2019 Apr;134:288-303.[2]. Zhen Dai, et al. Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. J Med Chem. 2022 Mar 24;65(6):5029-5043. |
| | Pyridine, 5-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-2-methyl- Preparation Products And Raw materials |
|